EXPAREL vs bupivacaine HCI in total knee arthroplasty4
Results from an EXPAREL phase 4, double-blind, randomized, controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a total knee arthroplasty study. Primary end points: area under the curve of visual analog scale pain intensity scores 12 to 48 hours postsurgery; total opioid consumption 0 to 48 hours postsurgery. Rescue opioids for pain were available upon patient request.
Learn more about opioid-free EXPAREL